ALG8蛋白截断变异杂合子个体轻度囊性肾病风险增加
在Geisinger-Regeneron DiscovEHR MyCode研究的174,172例患者中,236例携带ALG8蛋白截断变异(PTV)。这些变异与任何肾/肝囊肿诊断(OR 2.42)、囊性肾病(OR 3.03)和肾结石(OR 1.89)风险显著增加相关;盲法影像复核显示,≥30岁的ALG8 PTV杂合子出现≥4个肾囊肿(57.7% vs 7.7%)或双侧肾囊肿(69.2% vs 15.4%)的比例显著更高。UK Biobank数据显示ALG8 PTV杂合子ICD编码N28风险显著增加(3.85% vs 1.33%),但MyCode和UK Biobank中ALG8 PTV均与慢性肾脏病或肾衰竭无关。
要点
- ALG8 PTV杂合子与任何肾/肝囊肿诊断风险增加相关(OR 2.42)。
- ALG8 PTV杂合子囊性肾病风险增加(OR 3.03),但肝囊肿风险无显著差异。
- ALG8 PTV与慢性肾脏病或肾衰竭无显著关联。
核心结论
- ALG8基因的蛋白截断变异(PTV)导致轻度囊性肾病表型风险增加。
研究设计与样本
- 基于美国宾夕法尼亚州Geisinger-Regeneron DiscovEHR MyCode研究的观察性队列,纳入174,172例患者,其中236例携带ALG8 PTV。
- 对52例30岁以上的ALG8 PTV杂合子及相关非杂合子进行匹配队列的盲法CT和MRI影像复核。
- 利用公开的UK Biobank数据进行验证。
主要发现
- 在MyCode研究中,ALG8 PTV携带者任何肾/肝囊肿诊断风险显著增加(OR 2.42,95%CI 1.53-3.85)。
- 囊性肾病风险显著增加(OR 3.03,95%CI 1.26-7.31),肾结石风险显著增加(OR 1.89,95%CI 1.96-2.97)。
- 影像复核显示,ALG8 PTV杂合子出现≥4个肾囊肿的比例为57.7%,非杂合子为7.7%,差异显著。
- ALG8 PTV杂合子出现双侧肾囊肿的比例为69.2%,非杂合子为15.4%,差异显著;而≥1个肝囊肿的比例分别为11.5%和7.7%,无显著差异。
- 在UK Biobank中,ALG8 PTV杂合子ICD编码N28(肾/输尿管其他疾患)风险显著增加(3.85% vs 1.33%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ALG8 protein-truncating variants (PTVs) have previously been described in patients with polycystic liver disease and in some cases cystic kidney disease. Given a lack of well-controlled studies, we determined whether individuals heterozygous for ALG8 PTVs are at increased risk of cystic kidney disease in a large, unselected health system-based observational cohort linked to electronic health records in Pennsylvania (Geisinger-Regeneron DiscovEHR MyCode study). Out of 174,172 patients, 236 were identified with ALG8 PTVs. Using ICD-based outcomes, patients with these variants were significantly at increased risk of having any kidney/liver cyst diagnosis (Odds Ratio 2.42, 95% confidence interval: 1.53-3.85), cystic kidney disease (3.03, 1.26-7.31), and nephrolithiasis (1.89, 1.96-2.97). To confirm this finding, blinded radiology review of computed tomography and magnetic resonance imaging studies was completed in a matched cohort of 52 thirty-plus year old ALG8 PTV heterozygotes and related non-heterozygotes. ALG8 PTV heterozygotes were significantly more likely to have cystic kidney disease, defined as four or more kidney cysts (57.7% vs. 7.7%), or bilateral kidney cysts (69.2% vs. 15.4%), but not one or more liver cyst (11.5% vs. 7.7%). In publicly available UK Biobank data, ALG8 PTV heterozygotes were at significantly increased risk of ICD code N28 (other disorders of kidney/ureter) (3.85% vs. 1.33%). ALG8 PTVs were not associated with chronic kidney disease or kidney failure in the MyCode study or the UK Biobank data. Thus, PTVs in ALG8 result in increased risk of a mild cystic kidney disease phenotype.
引用
- Apple B, Sartori G, Moore B, et al. Individuals heterozygous for ALG8 protein-truncating variants are at increased risk of a mild cystic kidney disease. Kidney Int. 2022. PMID: 36574950. doi:10.1016/j.kint.2022.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。